# US 2018/0023144 A1 · Methods and nucleic acids for analyses of cell proliferative disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0023144 A1
- Document ID: US20180023144A1
- Status: Published application
- Kind: A1
- Application number: 15/672,858
- Filed: 2017-08-09
- Published: 2018-01-25
- Earliest claimed: 2007-12-11
- Assignees: Epigenomics AG
- Applicants: Epigenomics AG
- Inventors: Dimo Dietrich; Volker Liebenberg; Reimo Tetzner; Juergen Distler; Joern Lewin; Thomas Schlegel
- Web page: https://patentgrep.com/patent/US20180023144A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/154: Methylation markers
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/158: Expression markers
- C12Q 2600/16: Primer sets for multiplex assays
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The invention provides methods, nucleic acids and kits for detecting lung carcinoma. The invention discloses genomic sequences the methylation patterns of which have utility for the improved detection of said disorder, thereby enabling the improved diagnosis and treatment of patients.

## Claims

### Claim at position 1

1-21. (canceled)

### Claim 22

A method for detecting CpG methylation of FOXL2 in genomic DNA from a biological sample isolated from a subject having lung cancer, the method comprising:
(a) treating genomic DNA isolated from a biological sample obtained from the subject with at least one reagent or series of reagents that distinguishes between methylated and non-methylated CpG dinucleotides within at least one target region of the genomic DNA,
wherein the biological sample is selected from the group consisting of cells or cell lines, histological slides, biopsies, paraffin-embedded tissue, body fluids, blood plasma, blood serum, whole blood, isolated blood cells, sputum and biological material derived from the oral epithelium or from the lung, comprising bronchial lavage, bronchial alveolar lavage, bronchial brushing, and bronchial abrasion, and combinations thereof,
wherein the at least one target region of the genomic DNA comprises or is complementary to a sequence of at least 16 contiguous nucleotides of SEQ ID NO: 5, and wherein said contiguous nucleotides comprise at least one CpG dinucleotide sequence; and
(b) detecting the presence or absence of CpG methylation within the target region.

### Claim 23 (depends on 22)

The method of claim 22, wherein in step (a), the at least one reagent or series of reagents that distinguishes between methylated and non-methylated CpG dinucleotides converts cytosine bases that are unmethylated in the 5′-position thereof to uracil or to another base that is detectably dissimilar to cytosine in terms of hybridization properties; and wherein in step (b) detecting the presence or absence of CpG methylation within the target region comprises contacting the treated genomic DNA with an amplification enzyme and at least one primer comprising a contiguous sequence of at least 9 nucleotides that is identical or complementary to a sequence selected from the group consisting of SEQ ID NOs: 16, 17, 30 and 31, wherein the treated genomic DNA is either amplified to produce at least one amplificate, or is not amplified; thereby detecting presence or absence of CpG methylation of at least one CpG dinucleotide of a sequence selected from the group consisting of SEQ ID NOs: 16, 17, 30 and 31.

### Claim 24 (depends on 22)

The method of claim 22, wherein treating the genomic DNA, or the fragment thereof comprises use of a reagent selected from the group comprising of bisulfite, hydrogen sulfite, disulfite, and combinations thereof.

### Claim 25 (depends on 22)

The method of claim 22, wherein in step (a), the at least one reagent or series of reagents that allows distinguishing between methylated and non-methylated CpG dinucleotides is one or more methylation sensitive restriction enzymes, wherein step (a) further comprises digesting the genomic DNA with the one or more methylation sensitive restriction enzymes; and
wherein in step (b) detecting the presence or absence of CpG methylation within the target region comprises contacting the DNA restriction enzyme digest with an amplification enzyme and at least two primers suitable for the amplification of a sequence comprising at least one CpG dinucleotide of SEQ ID NO: 5, and detecting the presence or absence of an amplificate, thereby detecting the presence or absence of CpG methylation of at least one CpG dinucleotide of SEQ ID NO: 5.

### Claim 26 (depends on 22)

The method of claim 22, wherein the lung cancer comprises lung carcinoma.
